Economic and management consulting firm providing litigation, regulatory and strategy consulting to corporations and law firms.
Economic and management consulting firm providing litigation, regulatory and strategy consulting to corporations and law firms.
Bills clients by the hour for consultants and expert time, so how fully its staff are booked and how many large cases it has decide the year. Much of the work comes from law firms hiring economists to testify or advise on antitrust and merger reviews, with well-known academic experts affiliated with it.
Moat: narrow (brand, process know-how). Reputation for rigorous economic analysis in high-stakes litigation and antitrust matters drives repeat business.
Headquarters: Boston, Massachusetts · Founded: 1965 · Employees: 959
Size CRA International (CRAI) is a United States Industrials company (Miscellaneous Commercial Services) with a market value of $1.35B, the 2042nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $215.44 on 18 Nov 2026.
Performance Over six months the shares gained 45.6%, against -15.3% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 12.7% over the last twelve months (peer median +4.9%); the operating margin is 10.4% (peer median 8.1%).
Valuation It trades at 23.3× forward earnings against a peer median of 19.1× (9th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.2 points above its cost of capital (7.9% WACC).
Short interest Short interest is 4.8% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $824M | $752M | $687M | $624M | $591M |
| Revenue growth | — | +9% | +10% | +6% | — |
| Gross profit | $225M | $218M | $196M | $172M | $169M |
| EBITDA | $115M | $113M | $97.4M | $82.4M | $84.5M |
| Net income | $51.7M | $54.7M | $46.5M | $38.3M | $43.5M |
| Free cash flow | $8.16M | $18.6M | $33.1M | $57.7M | $20.3M |
| Capital expenditure | $6.54M | $3.87M | $16.6M | $2.37M | $3.81M |
| Total debt | $228M | $127M | $103M | $109M | $122M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CRA International CRAI | $1.35B | +46% | +13% | 10% | 23.3× | 6.6% |
| FTI Consulting FCN | $5.63B | +34% | +8% | 10% | 19.7× | -2.5% |
| Marsh McLennan MRSH | $97.7B | +26% | +8% | 24% | 18.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CRAI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.8% | -2.3% | 4th highest of 21 |
| 6-month return | +45.6% | -15.3% | highest of 21 |
| Distance from 52-week high | -5.2% | -35.4% | highest of 21 |
| Revenue growth (TTM) | +12.7% | +4.9% | 6th highest of 21 |
| Operating margin | 10.4% | 8.1% | 9th highest of 21 |
| Forward P/E | 23.3× | 19.1× | 9th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 6.6% | 8.8% | 8th least demanding of 17 |
| Growth delivered (Del g) | +8.1% | +12.6% | 7th lowest of 17 |
| Hurdle (Req g minus delivered) | -1.5 pp | -5.7 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | +9.2 pp | +0.3 pp | 3rd highest of 20 |
| EV / EBITDA | 13.6× | 7.8× | 3rd most expensive of 10 |
| Net debt / EBITDA | 1.8× | 1.9× | 5th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CRA International CRAI | United States | $1.35B | +46% | +13% | 10% | 23.3× | 6.6% | +8.1% |
| SBS 2384.T | Japan | $1.35B | +26% | +17% | 5% | 13.9× | -4.7% | +13.8% |
| PharmaBlock Sciences (Nanjing) 300725.SZ | China | $1.36B | +5% | +11% | 11% | 37.5× | 24.2% | +14.1% |
| China National Electric Apparatus Research Institute 688128.SS | China | $1.35B | -17% | +8% | 11% | 14.7× | 3.2% | +13.5% |
| China Security 600654.SS | China | $1.34B | -31% | -30% | -1% | n/a | 56.0% | +0.4% |
| Derichebourg DBG.PA | France | $1.37B | -18% | -3% | 5% | 8.8× | 6.7% | +6.3% |
| Changchun Up Optotech 002338.SZ | China | $1.34B | -41% | +22% | 2% | 43.1× | n/a | n/a |
| Clarivate CLVT | United States | $1.38B | -12% | -9% | 8% | 3.5× | 13.2% | +14.4% |
| Central Mine Planning & Design Institute CMPDI.NS | India | $1.38B | -22% | +10% | 33% | n/a | 4.5% | +18.7% |
| Shanghai Medicilon 688202.SS | China | $1.39B | +8% | +42% | -2% | 85.1× | n/a | n/a |
| TKC 9746.T | Japan | $1.31B | +22% | +5% | 20% | 19.1× | -10.1% | +5.7% |
| Shenzhen Ampron Technology 301413.SZ | China | $1.40B | -28% | +11% | 2% | 387.2× | n/a | n/a |
| Offcn Education Technology 002607.SZ | China | $1.40B | -40% | -2% | 13% | 34.7× | 15.7% | -27.6% |
| ICF International ICFI | United States | $1.40B | +14% | -5% | 8% | 10.4× | -2.5% | +4.4% |
| Shanghai MicroPort EP Medtech 688351.SS | China | $1.31B | -30% | +20% | 3% | 137.1× | 42.5% | +26.7% |
| AFRY AFRY.ST | Sweden | $1.42B | +5% | -4% | 7% | 12.5× | -2.2% | +6.3% |
| Yangzhou Tinfulong 603406.SS | China | $1.42B | -29% | -4% | 12% | n/a | 6.1% | +10.6% |
| Shanghai Foreign Service 600662.SS | China | $1.42B | -14% | +1% | 2% | 13.2× | n/a | n/a |
| Moltiply MOL.MI | Italy | $1.45B | +12% | +20% | 16% | 14.0× | 10.9% | +21.0% |
| Suzhou Recodeal Interconnect System 688800.SS | China | $1.26B | -68% | +5% | 9% | 31.0× | 22.7% | +38.9% |
| Concord Biotech CONCORDBIO.NS | India | $1.26B | -2% | +4% | 28% | 33.9× | 44.4% | +11.6% |